{
    "clinical_study": {
        "@rank": "14944", 
        "acronym": "PARC-T-D", 
        "brief_summary": {
            "textblock": "This study is a continuation of previous studies done in healthy volunteers to prove the\n      efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s\n      series of doses from low to high in men with low-to-no natural testosterone production to\n      measure their response to the varying doses.  The results of this study will inform further\n      studies which will be longer in length, as to the starting doses.  The study will be\n      conducted in London, U.K. at Barts and the London NHS Hospital and the London Clinic."
        }, 
        "brief_title": "A Dose Ranging Study to Examine Testagen\u2122 TDS\u00ae-Testosterone 5%", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypogonadotropism", 
        "condition_browse": {
            "mesh_term": "Hypogonadism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Hypogonadal Male subjects - morning testosterone level \u2264300 ng/dL (10.4 ng/L).\n\n          2. 18 and 75 years of age, inclusive.\n\n          3. The subject is willing and able to read, understand the Subject Information Sheet and\n             provide written informed consent.\n\n          4. The subject has a body mass index (BMI) within 18-30 kg/m2.\n\n          5. The subject is in otherwise good health as determined by medical history and physical\n             examination.\n\n          6. The subject is a non-smoker.\n\n          7. The subject must agree to comply with the placement of an indwelling catheter on two\n             separate occasions and the drawing of blood samples for the pharmacokinetic\n             assessments.\n\n          8. The subject is willing and able to comply with all testing and requirements defined\n             in the protocol.\n\n          9. The subject is willing and able to return to the study site for all visits.\n\n        Exclusion Criteria:\n\n          1. The subject has any relevant deviations from normal in physical examination,\n             electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the\n             investigator, particularly an elevated PSA reading >4.0 ng/ml or ALT and AST greater\n             than 2 times the upper limit of normal, clinically significant anemia (hematocrit\n             <35%) or renal dysfunction (creatinine >2mg/dL), active deep vein thrombosis,\n             thromboembolic disorders or history of these conditions.\n\n          2. The subject has had a clinically significant illness within 30 days preceding entry\n             into this study.\n\n          3. The subject has a history of significant neurological, hepatic, renal, endocrine,\n             cardiovascular, gastrointestinal, pulmonary, or metabolic disease.\n\n          4. The subject has a known allergy or history of hypersensitivity to Testosterone or\n             similar compounds.\n\n          5. The subject has used any prescription medication within 14 days or over-the-counter\n             (OTC) medication or alcohol within 48 hours of dosing or intends to use any\n             prescription or OTC medication during the study that may interfere with the\n             evaluation of study medication.\n\n          6. The subject has donated or lost a significant volume of blood (>450 mL) within four\n             (4) weeks of the study, and their haemoglobin concentration and haematocrit have not\n             returned to within 5% of normal.\n\n          7. The subject has a Hematocrit level  > 51%\n\n          8. The subject has a history of substance abuse or a current positive urine drug screen\n             or urine alcohol test.\n\n          9. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks\n             per week for males).\n\n         10. Subjects who have received an investigational drug or have used an investigational\n             device in the 30 days prior to study entry.\n\n         11. Subjects with an American Urological Association System Index for Prostatism score\n             greater than 7\n\n         12. Subjects with a history of prostate or breast carcinoma.\n\n         13. Subjects with prostatic mass on screening physical examination.\n\n         14. Subjects with a history of significant skin disease.\n\n         15. Subjects with a history of sleep apnea.\n\n         16. Subject with a partner with a history of breast cancer.\n\n         17. Subject with a partner of child bearing potential who is not willing to use adequate\n             contraception for the duration of the trial.\n\n         18. Subject whose partner is pregnant."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894308", 
            "org_study_id": "PARC-Testosterone-D1/09/13"
        }, 
        "intervention": {
            "description": "10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(TM)once daily for 7 days or until halted due to systemic or dermal reactions.", 
            "intervention_name": "Testosterone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Male Hormone Replacement", 
            "Multiple Dose", 
            "Single Period", 
            "Phase II", 
            "Dose Ranging", 
            "Adult Male Subjects", 
            "Testosterone Replacement"
        ], 
        "lastchanged_date": "August 1, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "EC1A 7BE"
                    }, 
                    "name": "The London Clinic, St. Bartholomews Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London,", 
                        "country": "United Kingdom", 
                        "zip": "EC1A 7BE"
                    }, 
                    "name": "Endocrine Studies Unit, Barts and the London NHS Trust"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine Testagen\u2122 TDS\u00ae-Testosterone 5% in Adult Male Subjects", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A pharmacokinetic measure of serum levels of testosterone in response to varying doses of from 10 to 70 mgs of Testosterone.", 
            "measure": "Dose Range", 
            "safety_issue": "Yes", 
            "time_frame": "1 week"
        }, 
        "reference": {
            "PMID": "16487220", 
            "citation": "Chik Z, Johnston A, Tucker AT, Chew SL, Michaels L, Alam CA. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br J Clin Pharmacol. 2006 Mar;61(3):275-9."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894308"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Skin response and general response to daily dosing over 7 days.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "1 Week"
        }, 
        "source": "Transdermal Delivery Solutions Corp", 
        "sponsors": {
            "collaborator": {
                "agency": "Barts & The London NHS Trust", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Transdermal Delivery Solutions Corp", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}